Blocking the CD40L:CR3 interaction by an anti-CD40L antibody or a cyclic peptide derived from the αMI binding site attenuated atherosclerosis in mice, which resulted in less inflamed, smaller, and more stable atherosclerotic lesions without affecting bleeding time and thrombus formation (200). Here, CD40LG is linked to atherosclerosis.